Core Viewpoint - BioPorto A/S has announced preliminary unaudited financial figures for 2025, providing guidance for 2026 and an update on its business strategy, indicating strong growth in its NGAL product line and a focus on expanding market adoption in the U.S. [1][4][11] Financial Performance - In Q4 2025, total revenue reached DKK 11.6 million, a 47% increase compared to Q4 2024, with a 52% increase at constant exchange rates [3][8] - For the fiscal year 2025, total revenue was DKK 40.3 million, up 11% from DKK 36.2 million in 2024, with a 13% increase at constant exchange rates [3][8] - Total NGAL revenue for FY 2025 was DKK 28.2 million, reflecting a 22% growth year-over-year [3][8] - The adjusted EBITDA loss for FY 2025 is estimated at approximately DKK 77 million, aligning with previous guidance [3][8] 2026 Financial Guidance - For 2026, BioPorto targets total revenue of DKK 48-58 million, representing a growth of 20-45% [6][9] - Total NGAL revenue is expected to grow by 20-50%, reaching DKK 33-42 million [6][9] - The adjusted EBITDA loss for 2026 is projected to be between DKK 50-60 million, indicating a decrease in loss of 22-35% compared to 2025 [9] Business Strategy and Market Adoption - The company is pursuing over 60 active hospitals in the U.S. by the end of 2026 as part of its "Forward" strategy [6][11] - By the end of 2025, there were 44 active hospitals using NGAL for Research Use Only (RUO), an increase of 8 from the previous year [14] - BioPorto is preparing for a clinical validation study for adults, with a pre-submission package to the FDA expected by the end of Q1 2026 [14] Future Aspirations - The company aims for revenue between DKK 150-200 million by FY 2028, with an adjusted EBITDA margin of at least 15% [9] - Cash flow is expected to turn positive in the second half of 2027, with current cash reserves projected to cover expenses through 2026 [9]

Core Viewpoint - BioPorto A/S has announced preliminary unaudited financial figures for 2025, providing guidance for 2026 and an update on its business strategy, indicating strong growth in revenue driven by its NGAL product line, particularly in the U.S. market [1][4][6]. Financial Performance - In Q4 2025, total revenue reached DKK 11.6 million, a 47% increase compared to Q4 2024, with a 52% increase at constant exchange rates [3][7]. - For the fiscal year 2025, total revenue was DKK 40.3 million, an 11% increase from DKK 36.2 million in 2024, with a 13% growth at constant exchange rates [3][7]. - Total NGAL revenue for FY 2025 was DKK 28.2 million, reflecting a 22% increase from the previous year [3][7]. - The adjusted EBITDA loss for FY 2025 is estimated at DKK 77 million, aligning with the guidance of a loss between DKK 75-80 million [3][7]. 2026 Financial Guidance - For 2026, BioPorto expects total revenue to be between DKK 48-58 million, representing a growth of 20-45% [6][8]. - Total NGAL revenue is projected to grow by 20-50%, reaching DKK 33-42 million [6][8]. - The adjusted EBITDA loss for 2026 is anticipated to be between DKK 50-60 million, indicating a decrease in loss of 22-35% compared to 2025 [8]. Business Strategy and Market Adoption - The company is focused on executing its "Forward" strategy, aiming to increase market adoption of its NGAL test, with a target of over 60 active hospitals in the U.S. by the end of 2026 [6][10][12]. - By the end of 2025, BioPorto had established 44 active hospitals for NGAL RUO, an increase of 8 from the previous year [12]. - The company is preparing for a clinical validation study for adults, with a pre-submission package to the FDA expected by the end of Q1 2026 [12]. Future Aspirations - BioPorto aims for revenue between DKK 150-200 million by FY 2028, with an adjusted EBITDA margin of at least 15% [8]. - The company expects to achieve positive cash flow in the second half of 2027, with current cash reserves projected to cover expenses through 2026 [8].

Core Insights - BioPorto A/S has announced a business strategy update, outlining its "Forward" strategic direction and aspirations towards 2028, with a focus on achieving cash flow positivity by the second half of 2027 [1][10] Strategic Direction - The "Forward" plan is a three-year strategy aimed at improving kidney health through actionable biomarkers, with a goal to transform kidney care globally [2] - The plan includes building market adoption, capturing high growth, and expanding the addressable market [2] Aspirations Towards 2028 - The company aims to be cash flow positive in the second half of 2027, requiring DKK 60-70 million in funding [10] - Revenue expectations for FY 2028 are set between DKK 150-200 million, with an adjusted EBITDA margin of at least 15% [9][16] Market Adoption Goals - By the end of 2026, BioPorto aims to have over 60 active hospitals in the US and reach 100 active hospitals globally by the end of 2027 [5][7] - The company plans to expand its market penetration in both pediatric and adult segments, leveraging enhanced clinical guidelines [7] Commercialization Strategy - BioPorto will focus on securing strategic partnerships with instrument manufacturers to drive product adoption and facilitate faster laboratory utilization of its biomarkers [5] - The company is preparing for EU IVDR certification, expected in 2027, to support its European market growth [6] Product Development and Market Expansion - The company intends to broaden its product portfolio to address additional clinical settings relevant to the NGAL biomarker, with a goal of having over 170 active hospitals globally by the end of 2028 [8]